Caribou expects these PD-1 knockout allogeneic CAR T therapies may overcome durability concerns to deliver therapies that are as effective as autologous anti-CD19 CAR T therapies but at a fraction of the cost. Caribou was co-founded in 2011 by, among others, CRISPR pioneer and Nobel laureate Jennifer Doudna.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only 8,25 € per issue
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
About this article
Cite this article
Caribou’s first CRISPR CAR-T impresses.
Nat Biotechnol 40, 807 (2022). https://doi.org/10.1038/s41587-022-01371-6